Sentinel Capital Partners acquires WellSpring

Drug maker manufactures prescription, OTC drugs

NEW YORK — Sentinel Capital Partners has acquired Sarasota, Fla.-based WellSpring Pharmaceutical, the private equity firm said Monday.

Sentinel, which describes itself as investing in lower middle-market companies, said it bought the manufacturer of prescription and OTC drugs, which manufactures its products in Ontario, alongside Ancor Capital Partners. Financial terms of the deal were not disclosed.

"WellSpring is an innovator that provides quality pharmaceutical products and related services across a diverse set of end markets," Sentinel partner Eric Bommer said. "The opportunity to invest alongside Ancor was also a strong incentive for us."

Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

Login or Register to post a comment.